Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood draw might reveal hidden eye lymphoma

NCT ID NCT05388838

Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study tests whether a blood test can help doctors tell apart uveitis caused by lymphoma from other types of uveitis. Uveitis is an eye inflammation that can lead to vision loss, and in some cases it is a sign of a rare eye lymphoma that may spread to the brain. The researchers will compare blood samples from 60 people with untreated eye lymphoma and people with non-cancerous uveitis to see if a specific immune cell pattern can flag the cancer. If the test works, it could offer a faster, less invasive way to diagnose this serious condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood sample for NK cell phenotype analysis
What this could lead to
If successful, this could lead to a simple blood test to quickly identify lymphoma in uveitis patients, reducing diagnostic delays and potentially preventing brain involvement.
What could go wrong
This is an early-stage study with a small number of participants. The blood test may not reliably distinguish lymphoma from other causes of uveitis, and further validation is needed before it could be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jun 2022

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: GENERAL CRITERIA * Male or female over 18 years of age, * Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research, * Patient affiliated to the social security system or beneficiary of such a system, * Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1). SPECIFIC CRITERIA \- Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \< 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6). Exclusion Criteria: * -GENERAL CRITERIA * Patient participating in an ongoing clinical trial at the time of the inclusion visit, * Pregnant women, women in labor or nursing mothers, * Persons deprived of liberty by a judicial or administrative decision, * Persons under psychiatric care, * Persons admitted to a health or social institution for purposes other than research, * Persons of full age who are subject to a legal protection measure (guardianship, curatorship). SPECIFIC CRITERIA * Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain, * Patient with another systemic cancer that is evolving or in remission \< 2 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract cerebral lymphoma glaucoma intraocular lymphoma lymphoma preretinal fibrosis retinal detachment uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma NK-cell lymphoma Uveitis

Contacts and locations

Locations

  • Service d'Hématologie Clinique, Hôpital Lyon Sud

    Lyon, 69310, France

  • Service d'Ophtalmologie, Hôpital de la Croix-Rousse, GHN

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.